Clinical Scorecard: Uncommon Spontaneous Intracerebral Hemorrhage Linked to Lenvatinib in Advanced Hepatocellular Carcinoma Without Traditional Risk Factors: A Case Study and Literature Review

At a Glance

Key Highlights

• Lenvatinib is associated with an increased risk of hemorrhagic events.
• A case of spontaneous lobar ICH in a patient with advanced HCC is reported.
• The patient had no traditional risk factors for ICH.
• MRI findings indicated a large lobar ICH without evidence of metastatic tumor.
• Close monitoring is essential for patients presenting new neurological symptoms during treatment.
• The patient had a history of treatment with atezolizumab and bevacizumab prior to lenvatinib.

Guideline-Based Recommendations

Diagnosis

Management

Monitoring & Follow-up

• Regular neurological assessments and imaging follow-up are advised, ideally every 1-3 months.

Risks

Patient & Prescribing Data

Lenvatinib was administered at a standard dose of 12 mg once daily for approximately seven months prior to the ICH event.

Clinical Best Practices

• Maintain vigilance for neurological symptoms in patients receiving lenvatinib.
• Consider the potential for ICH even in the absence of traditional risk factors.
• Educate patients on recognizing and reporting new neurological symptoms promptly.

Related Resources & Content

• REFLECT trial
• VEGFR-targeted therapies
• Clinical trials on lenvatinib